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Abstract
Background: Obesity has been shown to affect heart rate variability (HRV). Adipokines
(hormone-like peptides secreted by adipose tissue) display several bioactivities and have an
impact on the cardiovascular system. The aim of the study was to evaluate the impact of obesity
(BMI ≥ 30) and adipokines (leptin, adiponectin and resistin) on HRV.
Methods: In 43 obese and 38 non-obese males with acute myocardial infarction, plasma
adipokines were determined. 24-hour Holter ECG with time and frequency domain HRV
analysis was performed.
Results: Anthropometric measurements, leptin and resistin were significantly higher and
adiponectin was lower in the obese than in the non-obese group. SDNN, SDANN, SDNN-i,
rMSSD, p-NN50 and HF were reduced in obese patients, whereas LF/HF was higher. Waist
circumference was a better correlate of HRV parameters than body mass index. Several asso-
ciations between HRV parameters and adipokines were observed: between SDNN and leptin
(r = –0.32; p < 0.001) and resistin (r = –0.26; p < 0.05); SDANN and leptin (r = –0.26; p < 0.05)
and resistin (r = –0.29; p < 0.001); SDNN-i and resistin (r = –0.40; p < 0.001); LF and
leptin (r = 0.22; p < 0.05); HF and resistin (r = –0.22; p < 0.05); LF/HF and leptin (r = 0.46;
p < 0.001) and resistin (r = 0.44; p < 0.001).
Conclusions: Obesity is related to sympathovagal imbalance characterized by depressed
parasympathetic tone and increased sympathetic activity. The relation between blood leptin
and resistin concentration to the HRV parameters may indicate a possible link between
adipokines and disturbances of the autonomic nervous system. (Cardiol J 2008; 15: 43–49)
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Introduction
Heart rate variability (HRV) is a result of the
influence of the autonomic nervous system on the
heart. During the last two decades a decreased HRV
has been recognized as a factor related to cardio-
vascular mortality, including sudden cardiac death
[1, 2]. The time domain method of evaluating HRV
is considered ideal for the analysis of long-term re-
cordings and assessment of overall HRV [3].
Excess body fat not only promotes clusters for
cardiovascular risk factors [4] but is an independ-
ent cardiovascular risk factor [5]. Obesity in patients
with established coronary artery disease worsens
the prognosis [6] and is associated with acute coro-
nary syndromes [7]. It has been shown that obesity
is related to disorders of the autonomic nervous sys-
tem independently and due to coexisting diabetes,
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hyperinsulinemia, dyslipidemia and arterial hyper-
tension [8–12].
Adipose tissue secretes adipokines — hor-
mone-like peptides which have an impact on glu-
cose and lipid metabolism, inflammatory process
and other bioactivities [13]. Recently the role of the
adipokines in HRV has attracted attention. Leptin,
a strong correlate of the degree of obesity, stimu-
lates the sympathetic nervous system [14, 15] and
the relation between serum leptin levels and sym-
pathetic activity independently of the amount of
observed body fat was observed [16]. It has been
suggested that increased plasma leptin concentra-
tion may be a result of the selective tissue resist-
ance to its satiety and weight-reducing effect
whereas the sympathoexcitatory action of leptin is
preserved [17]. Low serum concentrations of adi-
ponectin, an adipokine considered as a protective
cardiovascular factor [18], was associated with sym-
pathovagal balance favouring relative sympathetic
activation in patients with type-2 diabetes [19].
Resistin, an adipokine potentially linked to athero-
genesis [20], has not yet been demonstrated to be
linked with the automatic nervous system.
At present, as the rates of obesity and its sequel
are rising steadily due to the Western lifestyle [21],
all the aspects of adverse effects of obesity on the
cardiovascular system seem to be an important issue.
The aim of the study was to evaluate the im-
pact of obesity and selected adipokines (leptin, adi-
ponectin and resistin) on cardiac autonomic nerv-




From the population of patients with first AMI
successfully treated with primary percutaneous
coronary intervention (TIMI flow grade 3, residual
stenosis < 30%), 43 obese males (BMI ≥ 30) aged
up to 65 years were selected for the study group.
The control group consisted of 38 non-obese males
(BMI < 25).
Diagnosis of AMI was based on clinical symp-
toms, electrocardiographic signs and elevation of
myocardial necrotic markers. Exclusion criteria
were conditions that either made HRV analysis
impossible or had a significant impact on HRV pa-
rameters: clinical instability (Killip III–IV class),
atrial fibrillation, atrioventricular or bundle branch
block, temporary or permanent stimulation, signifi-
cant valvular heart disease or severe hypertension.
Pharmacological treatment with aspirin, clopidogrel,
statins, beta-blockers, inhibitors of angiotensin II,
nitrates and diuretics did not significantly differ be-
tween the groups.
The study was approved by the Internal Ethics
Committee of the Medical University of Łódź, and
each patient gave informed consent.
Anthropometric measurements
Body mass index (BMI), calculated as the body
weight divided by the square of the height (kg/m2),
was used as a marker of obesity. Weight and height
were measured while the subjects were fasting. Pa-
tients were designated as obese when BMI exceeded
30 kg/m2 and were considered non-obese when BMI
was below 25 kg/m2. Waist circumference was
measured at the widest diameter between the
xiphoid process of the sternum and the iliac crest.
Heart rate variability analysis
24-hour Holter ECG was performed in all pa-
tients on the third or fourth day after AMI.
A three-lead digital ECG recorder with Oxford Hol-
ter analyzer was used. This allowed automatic and
manual analysis of two orthogonal bipolar ECG leads
(CM V5 and CM V6) with a mean duration of
22.8 ± 1.2 hours. Supraventricular and ventricular
ectopic beats, as well as artefacts, were identified
and manually eliminated from the analysis. Accord-
ing to the present standard [3] long-term time
domain and frequency domain variables, 24-hour
recordings were analyzed with a sampling rate
of 292 Hz.
Time domain variables:
— SDNN — the standard deviation of all intervals
between adjacent QRS complexes resulting
from sinus node depolarization (NN), i.e. the
square root of variance, reflects all the cyclic
components responsible for variability in the
period of recording and is considered as an es-
timate of overall HRV, encompassing vagal and
sympathetic influences;
— SDANN — the standard deviation of the aver-
age NN intervals assesses long-term compo-
nents that influence HRV, mainly the sympa-
thetic output;
— SDNN index (SDNN-i) — the mean of the
5-minute standard deviations of NN intervals
calculated over 24 hours measures the varia-
bility due to cycles shorter than five minutes
and reflects parasympathetic activity;
— rMSSD — the root mean square of successive
differences in NN intervals is considered as an
estimate of short-term components of  HRV,
corresponding to parasympathetic activity;
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— p-NN50 — the proportion derived by dividing
NN50 (the number of interval differences of
successive NN intervals greater than 50 ms)
by the total number of NN intervals. This is
a measure of parasympathetic activity.
Frequency domain variables:
— LF (0.04–0.15 Hz) — the low frequency range
reflects the mixture of sympathetic and para-
sympathetic activation;
— HF (0.15–0.40 Hz) — the high frequency range
gives a measure of vagal control;
— LF/HF — an index that provides an assessment
of the symphatovagal balance.
LF and HF were transformed into natural lo-
garithms (ln).
Laboratory measurements
Fasting blood samples for measurements of
adipokines were taken on the day following admis-
sion, and plasma was frozen at –70° until analysis
with a sandwich enzyme-linked immunosorbent
assay (ELISA).
Echocardiographic examination
Echocardiographic study was performed on the
second-third day after admission with a Sonos 5500
S3 probe. A harmonic option was used to enhance
the visualization of the endocardium. Left ventricu-
lar ejection fraction was assessed at 4- and 2-cham-
ber apical views with biplane Simpson’s formula to
evaluate left ventricular systolic function.
Statistical analysis
Continuous data are expressed as mean ±
± standard derivation (SD). Variables were log-
-transformed before statistical analysis, if neces-
sary. Comparisons between groups were performed
using the two-tailed, non-paired Student’s t-test or
Mann-Whitney test, as appropriate. Categorical
variables are presented as number and percentage
of patients, and comparisons between analyzed
groups were analyzed with the c2 test. Associations
between analyzed parameters were examined us-
ing Spearman’s correlation coefficient. A p value
of < 0.05 was considered statistically significant.
Statistica software (version 5.0) was used for sta-
tistical analysis.
Results
The clinical characteristics of the study group
are presented in Table 1. There was no significant
difference in mean age, time since the onset of
symptoms to admission, or localization of AMI and
left ventricular ejection fraction between the study
groups. The occurrence of most cardiovascular risk
Table 1. Clinical characteristics of the study groups.
Obese Non-obese p
(n = 43)  (n = 38)
Age 54.06±7.04 55.26±6.62 NS
Interval between the chest pain 3.93±2.25 4.52±2.60 NS
and admission to hospital [h]
Anterior myocardial infarction 18 (41.86%) 16 (42.11%) NS
Ejection fraction (%) 57.21±8.82 55.63±8.52 NS
Body mass index [kg/m2] 32.00±1.78 23.63±1.27 < 0.0001
Waist circumference [cm] 112.16±7.83 88.08±7.21 < 0.0001
Smoking 27 (62.79%) 24 (63.16%) NS
Hypertension 26 (60.47%) 15 (40.47%) NS
Systolic blood pressure 123.95±10.50 119.73±12.14 NS
Diastolic blood pressure 75.34±6.93 73.42±8.06 NS
Diabetes mellitus 13 (30.23%) 7 (18.42%) NS
HDL-cholesterol < 40 mg/dL 17 (39.53%) 7 (18.42%) < 0.05
Dyslipidemia 31 (70.09%) 23 (60.53%) NS
Leptin [ng/mL] 44.50±19.01 17.23±14.42 < 0.0001
Resistin [ng/mL] 27.26±11.49 15.99±9.09 < 0.0001
Adiponectin [ng/mL] 7.09±4.36 10.81±6.52 < 0.01
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factors (hypertension, diabetes, smoking, dyslipi-
demia) was similar in both groups. A significant dif-
ference was observed only in the proportion of pa-
tients with high-density lipoprotein cholesterol
(HDL-CH) < 40 mg/dL. The assessed anthropo-
metric measurements (BMI and waist circumfer-
ence), as well as mean blood leptin and resistin con-
centration, were significantly higher and mean ad-
iponectin concentration was significantly lower in
obese than in non-obese group (Table 1).
As shown in Table 2, significantly lower val-
ues of overall HRV expressed as lower SDNN were
observed in obese subjects. This was due to the
reduction in both long-term HRV (SDANN) and
short-term HRV (SDNN-i). Moreover, lower values
of other parameters reflecting parasympathetic tone
(rMSSD, p-NN50, HF) were observed in obese pa-
tients. Higher values of LF/HF in obese patients
indicated the advantage of sympathetic over para-
sympathetic activation in these subjects.
There were more HRV correlates for waist cir-
cumference (SDNN, SDANN, SDNN-i, rMSSD, HF
and LF/HF) than for BMI (SDNN, SDNN-i and LF/
/HF). Mean blood leptin and resistin concentration
were negatively related to SDNN and positively
related to LF/HF. Leptin affected parameters that
chiefly reflect the sympathetic output (SDANN and
LF), whereas resistin affected parameters of both
sympathetic and parasympathetic activity (SDANN,
SDNN-i and HF). No significant association be-
tween adiponectin and parameters of HRV was re-
vealed (Table 3).
Discussion
In patients surviving an AMI, the association
between depressed HRV and an increase in the risk
of death, mainly arrhythmic, has been widely eluci-
dated in small studies and larger randomized stud-
ies [1, 2]. Obesity in patients with coronary artery
disease worsens the prognosis [6] and its impact on
the autonomic nervous system could be one of the
possible ways of this deleterious action.
Several authors have observed that obesity and
weight loss affect HRV [9, 22–25]. However, oth-
ers [8, 26, 27] have detected no association between
HRV and BMI. It has been documented with vari-
ous methods in experimental [28] and clinical stud-
ies [9, 29–31] that parasympathetic activity is de-
creased in obesity. Our results seem to confirm that
observation as there were significantly lower
SDNN-i, MSSD, p-NN50 and HF in obese than in
control subjects. Moreover, we demonstrated
a negative correlation between anthropometric
measurements (especially waist circumference) and
the parameters reflecting parasympathetic activi-
ty. Disparate results come from the study by Kim
et al. [8] who revealed a negative relation between
r-MSSD and waist to hip ratio (r = –0.38; p<0.05).
Although high blood leptin concentration is of-
ten accompanied by sympathetic activation, stud-
ies on the norepinephrine kinetics assessed with
the use of [3H]-labelled norepinephrine and analy-
sis of the regional oxygen consumption revealed
that regional sympathetic nervous system activity is
heterogeneous in the obese state, and it was suggest-
ed that sympathetic activation spares the sympa-
thetic nerves directed to the heart [32]. However,
Table 3. Correlation between parameters of heart rate variability and anthropometric measurements
and adipokines.
SDNN SDANN SDNN-i rMSSD p-NN50 LF HF LF/HF
Body mass index –0.23*** –0.17 –0.29** –0.16 –0.06 0.10 –0.20 0.29*
Waist circumference –0.30** –0.26*** –0.40* –0.24*** –0.17 0.03 –0.32* 0.46*
Leptin –0.32* –0.26*** –0.19 –0.17 –0.02 0.22*** –0.14 0.46*
Resistin –0.26*** –0.29* –0.40* –0.15 –0.12 0.07 –0.22*** 0.44*
Adiponectin 0.06 0.10 0.16 0.16 0.01 –0.07 0.05 –0.14
*p < 0.001; **p < 0.01; ***p < 0.05
Table 2. Parameters of heart rate variability in
the groups of obese and non-obese patients.
Obese Non-obese p
(n = 43)  (n = 38)
SDNN 104.16±26.81 119.49±28.62 < 0.05
SDANN 87.60±23.47 99.05±27.62 < 0.05
SDNN-i 54.57±27.06 67.36±28.10 < 0.05
r-MSSD 33.80±15.16 41.29±16.27 < 0.05
p-NN50 5.36±4.66 7.68±5.25 < 0.05
LF ln 6.34±0.63 6.41±0.62  NS
HF ln 5.24±0.63 5.59±0.53 < 0.01
LF/HF 1.22±0.08 1.15±0.08 < 0.01
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the results of the present study show sympathetic
overactivity in obesity as reflected by significantly
lower SDANN in obese than in lean subjects, and
the negative relation between SDANN and waist
circumference, leptin and resistin. This result is
consistent with Rabbia et al. [24] who observed the
tendency for lower values of SDANN in obese pa-
tients. Moreover, Karason et al. [23] and Naut et
al. [24] have shown the increment in SDANN after
weight-loss. During sympathetic activation and in
conditions known for increased circulating catecho-
lamines such as heart failure and aging LF power
has been identified as a parameter reflecting main-
ly sympathetic activity, whereas in stable conditions
it reflects a fusion of parasympathetic and sympa-
thetic impact [33]. No significant difference in LF
between obese and non-obese patients was observed
in our study and in the study of Rabbia et al. [22].
However, in agreement with Paolisso et al. [16]
plasma leptin concentration is positively associat-
ed with LF. Disparate results were revealed by Kim
et al. [8] who showed a negative correlation be-
tween LF and waist to hip ratio.
In agreement with previous reports [9, 10, 16]
we observed a shift in the sympathovagal balance
toward an increase in sympathetic activation ex-
pressed as an increased LF/HF in obese patients.
We also noted the positive association between
plasma leptin and resistin concentration and LF/HF.
In our study, adiponectin was not related to any
HRV variables. Information from other studies con-
ducted in groups of patients with type-2 diabetes,
suggests that there are possible links between hy-
poadiponectinemia and cardiac sympathetic activi-
ty. Wakabayashi et al. [34] showed an independent
negative association between blood adiponectin
concentration and 24-hour LF/HF ratio. In the study
by Takahashi et al. [35], adiponectin did not corre-
late with HF power or LF/HF, but cardiac scintig-
raphy with radioactive-labelled metaiodobenzylgua-
nidine (123I-MIBG — an analogue of guanethidine
which accumulates in norepinephrine storage gran-
ules in postganglionary sympathetic neurons)
showed that in type-2 diabetes, low blood adiponec-
tin concentration was associated with sympathetic
activation. The authors revealed that in patients with
hypoadiponectinemia there is a lower delayed myo-
cardial uptake and higher washout rate of 123I-MIBG.
We have not come across any paper concern-
ing the relationship between resistin and  HRV pa-
rameters; however, in our group of patients these
associations were similar to those concerning lep-
tin, i.e. resistin was negatively associated with
SDNN, SDANN, SDNN-i and HF and positively
associated with LF/HF. Attempts to explain these
results led us to the studies on hyperresistinemia,
presumably induced by cytokines [36], interaction
between inflammatory and autonomic systems [37–39]
and, in the end, to a possible link between resistin,
inflammation and sympathetic activation. The HRV
correlates of resistin presented in this study are
similar to the correlates of C-ractive protein in other
studies [39, 40]. This observation is coherent with
the previously reported association between blood
resistin and C-ractive protein concentration [41, 42].
A limitation of our study is that in each patient
a different cluster of the possible cofactors might
have an impact on cardiac autonomic control. It has
been shown that lower HRV is observed in metabolic
disorders (hypertension, type-2 diabetes and dysli-
pidemia) especially when clustering [43], and it is
very unusual for the obese individual to be free from
any of these problems. Although the medication was
almost identical in the whole study group, the applied
doses differed in individual patients, and might have
affected our results.
This study was performed exclusively on men,
so the results cannot be generalized for the whole
population. The gender-related differences in fat
distribution, namely the presence of more abun-
dant subcutaneous fat in women and of visceral fat
in men, that have an impact on cardiovascular risk
profile [44] may influence the mode of HRV mod-
ulation.
Conclusion
Obesity is related to sympathovagal imbalance
characterized by depressed parasympathetic tone
and increased sympathetic activity. The relation
between blood leptin and resistin concentration to
the HRV parameters may indicate a possible link
between adipokines and disturbances of the auto-
nomic nervous system.
Future investigations on larger groups of pa-
tients, with HRV response to stimuli, complex eval-
uation of automatic nervous system including
baroreceptor reactivity as well as prospective study
with follow-up observation are warranted to thor-
oughly elucidate the impact and mechanism of ad-
verse effects of obesity on cardiac function.
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